The following is a summary of “Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare—the DEMONSTRATE database,” published in the April 2025 ...

A groundbreaking new drug called zilebesiran has shown that just one injection every six months, when added to standard pills, can significantly lower blood pressure by 4 to 12 points depending on the ...

Researchers have found that prescribing guideline-directed medical treatment (GDMT), regardless of the number of medications, can improve survival rates in patients 90 years of age and older following ...

with adverse events consistent with the known effects of targeting the renin-angiotensin-aldosterone system -- an increased risk of hyperkalemia and hyponatremia and decreases in the eGFR ...

Please provide your email address to receive an email when new articles are posted on . Dysregulated aldosterone production, sometimes driven by obesity, can cause hypertension. Targeted therapies ...

is a vitally important part of the body's blood pressure regulation system. More specifically, this is done through the classical renin-angiotensin-aldosterone system (RAAS) pathway. Inappropriate ...

The novel selective aldosterone synthase inhibitor BI 690517 (up to 10 mg daily) with concurrent renin-angiotensin-system (RAS) inhibition, with or without the SGLT2 inhibitor empagliflozin ...

Darcy Adin, DVM, DACVIM (Cardiology), explains her research on the renin-angiotensin‐aldosterone system In an interview with Darcy Adin, DVM, DACVIM (Cardiology), she explains what the ...

Discontinuing or reducing renin-angiotensin-aldosterone system inhibitor treatment may have negative outcomes for patients with hyperkalemia, but it is a common practice in many clinics ...